Today, a "darling" company in the media thanks to new obesity drugs and other good news hitting the media airwaves is selling off. In fact, its having its worst day relative to its sector peers in many years.
From the Desk of Steve Strazza and Alfonso Depablos
Today’s most significant insider transaction comes in a Form 4 filing by Decheng Capital Management, a hedge fund focused on investing in early-stage life science companies.
This is definitely a "hard" trade. Hard because it's already had a tremendous run this month. Hard because it's in a name that people often don't associate with big bull runs, in a sector that definitely isn't sexy.
